Physician profile

Daniel Arnett

Cardiovascular Disease · Burlington, MA

NPI 1972846004

$1,763.77

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$179.89
Consulting Fee$85.00
Honoraria$53.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $570.00 2022-2024
Abbott Laboratories $551.89 2019-2021
Becton, Dickinson and Company $155.00 2022
Amgen INC. $124.46 2023 Repatha
Pfizer INC. $95.86 2019
Janssen Pharmaceuticals, INC $94.39 2019
Merck Sharp & Dohme LLC $63.74 2022
Baxter Healthcare $55.43 2023 Hillrom - Cardiac Ambulatory Monitor
W. L. Gore & Associates, INC. $53.00 2024 Gore Cardioform Septal Occluder

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Arnett

$1,763.77

in general payments reported 2019-2025

Years
2019-2024
Top company
Medtronic, INC.

https://glasscript.com/doctor/761422/daniel-arnett

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.